Advertisement

Current Oral Health Reports

, Volume 3, Issue 2, pp 74–81 | Cite as

Immunotherapy for Head and Neck Squamous Cell Carcinoma

  • Rebecca C. Hoesli
  • Jeffrey S. MoyerEmail author
Oral Neoplasia (F Alawi and A Le, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Oral Neoplasia

Abstract

Head and neck squamous cell carcinoma has been found to be an immunosuppressive malignancy, with many defects in the host immune system contributing to the progression of disease. A greater understanding of these defects has lead to the identification and investigation of new therapeutic strategies, targeting immune system dysfunction in an effort to improve the outcomes of this disease. This article provides a brief review of the knowledge regarding the immune defects present in head and neck cancer, as well as a review of the current therapeutic strategies being investigated for use.

Keywords

Immunology Squamous cell carcinoma Head and neck cancer 

Notes

Compliance with Ethical Standards

Conflict of Interest

Rebecca C. Hoesli and Jeffrey S. Moyer declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004;10:3755.CrossRefPubMedGoogle Scholar
  2. 2.
    Hoffmann TK, Dworacki G, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002;8:2553–62.PubMedGoogle Scholar
  3. 3.
    Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res. 1999;5:1369.PubMedGoogle Scholar
  4. 4.•
    Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 2015;33:28. This article provides an excellent review of immunology related to carcinoma. It provides excellent background information of immunology in general, and provides a nice review of the state of the field currently.CrossRefGoogle Scholar
  5. 5.
    Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL. Characteristics of CD4 + CD25+ regulatory t cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer. 2005;92:913–20.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL. A unique subset of CD4 + CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppresion in the tumor microenvironment. Clin Cancer Res. 2007;13:4345–54.CrossRefPubMedGoogle Scholar
  7. 7.
    Ferris R, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res. 2006;12:3890–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Whiteside TL. Immune cells in the tumor microenvironment: mechanisms responsible for functional and signaling defects. Adv Exp Med Biol. 1998;451:161–71.Google Scholar
  9. 9.
    Dasgupta S, Bhattacharya-Chatterjee M, O’Malley BW, Chatterjee SK. Inhibition of NK cell activity through TGF-beta1 by down-regulation of NKG2D in a murine model of head and neck cancer. J Immunol. 2005;175:5541–50.CrossRefPubMedGoogle Scholar
  10. 10.
    Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000;6:1755–66.PubMedGoogle Scholar
  11. 11.
    Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253–68.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Raval RR, Sharabi AB, Walker AJ, Drake CG, Sharma P. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer. 2014;2:14.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Gildener-Leapman N, Ferris RL, Bauman JE. Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol. 2013;49:1089–96.CrossRefPubMedGoogle Scholar
  14. 14.
    Grandis JR, Tweardy DJ. TGF-alpha and EGFR in head and neck cancer. J Cell Biochem Suppl. 1993;17F:188–91.CrossRefPubMedGoogle Scholar
  15. 15.
    Eisma RJ, Spiro JD, Kreutzer DL. Role of angiogenic factors: coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous carcinoma. Laryngoscope. 1999;109:687–93.CrossRefPubMedGoogle Scholar
  16. 16.
    Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90:824–32.CrossRefGoogle Scholar
  17. 17.
    Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 2013;19:1858–72.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol. 2010;28:4390–9.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Bauman JE, Ferris RL. Integrating novel therapeutic monoclonal antibodies in the management of head and neck cancer. Cancer. 2014;120:624–32.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, et al. Phase III randomized, placebo-controlled trial of docetaxel with or without Gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol. 2013;31:1405–14.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, et al. Cisplatin and radiotherapy with or without Erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol. 2013;31:1415–21.CrossRefPubMedGoogle Scholar
  22. 22.
    Giralt J, Trigo J, Nuyts S, Ozsahin M, Skiadowski K, Hatoum G, et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015;16:221–32.CrossRefPubMedGoogle Scholar
  23. 23.
    Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78.CrossRefPubMedGoogle Scholar
  24. 24.
    Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer. 2008;112:2710–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Licitra L, Mesia R, Rivera F, Remenar E, Hitt R, Erfan J, et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol. 2011;22:1078–87.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Licitra L, Storkel S, Kerr KM, Cutsem EV, Pirker R, Hirsch FR, et al. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer. 2013;49:1161–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Basavaraj C, Sierra P, Shivu J, Melarkode R, Montero E, Nair P. Nimotuzumab with chemoradiation confers a survival advantage in treatment-naive head and neck tumors over expressing EGFR. Cancer Biol Ther. 2010;10:673–81.CrossRefPubMedGoogle Scholar
  28. 28.
    Reddy BK, Lokesh V, Vidyasagar MS, Shenoy K, Babu KG, Shenoy A, et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients. Oral Oncol. 2014;50:498–505.CrossRefPubMedGoogle Scholar
  29. 29.
    Swanson MS, Sinha UK. Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer—review of current data. Oral Oncol. 2015;51:12–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26.CrossRefPubMedGoogle Scholar
  32. 32.
    Jie H, Schuler PJ, Lee SC, Srivastava RM, Argiris A, Ferrone S, et al. CTLA-4+ regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res. 2015;75:2200–10.CrossRefPubMedGoogle Scholar
  33. 33.
    Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.CrossRefPubMedGoogle Scholar
  34. 34.
    Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.CrossRefPubMedGoogle Scholar
  35. 35.
    Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011;47:1148–53.CrossRefPubMedGoogle Scholar
  36. 36.
    Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63:6501–5.PubMedGoogle Scholar
  37. 37.
    Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–75.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Seiwert TY. A phase IB study of MK-3475 in patients with human papillomavirus (HPV)- associated and non-HPV associated head and neck (h/n) cancer. 2014 ASCO Annu Meet. 32 2014.Google Scholar
  39. 39.•
    Starr P. Encouraging results for pembrolizumab in head and neck cancer. Am Health Drug Benefits. 2015;8:16. This study has not yet published its final results, but results are encouraging showing improvement over Cetuximab for treatment of HNSCC. These results if they show improvement over Cetuximab, would provide evidence of another immunologic target for squamous cell carcinoma.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Seiwert TY, Burtness B, Weiss M, Eder JP, Yearley J, Murphy E, Nebozhyn M, McClanahan T, Ayers M, Lunceford J, Mehra R, Heath K, Cheng J, Chow L. Inflamed-phenotype gene expression signatures, and in particular a gamma-interferon signature, predicted benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. ASPO. 2015.Google Scholar
  41. 41.
    Segal NH, Antonia SJ, Brahmer JR, Maio M, Blake-Haskins A, Li X, Vasselli J, Ibrahim RA, Lutzky J, Khleif S. Preliminary data from a multi-arm expansion study of medi4736, an anti-pd-l1 antibody. ASCO Annu Meet. 2014.Google Scholar
  42. 42.
    Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol. 1995;146:1029–39.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–64.CrossRefPubMedGoogle Scholar
  44. 44.
    Teknos TN, Cox C, Yoo S, Chepeha DB, Wolf GT, Bradford CR, et al. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck. 2002;24:1004–11.CrossRefPubMedGoogle Scholar
  45. 45.
    Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2:1096–103.CrossRefPubMedGoogle Scholar
  46. 46.
    Johnson BF, Clay TM, Hobeika AC, Lyerly HK, Morse MA. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther. 2007;7:449–60.CrossRefPubMedGoogle Scholar
  47. 47.
    Kyzas PA, Cunha IW, Ioannidis JPA. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005;11:1434–40.CrossRefPubMedGoogle Scholar
  48. 48.
    Argiris A, Karamouzis MV, Gooding WE, Branstetter BF, Zhong S, Raez LE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2011;29:1140–5.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Seiwert TY, Haraf DJ, Cohen EE, Stenson K, Witt ME, Dekker A, et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008;26:1732–41.CrossRefPubMedGoogle Scholar
  50. 50.
    Salama JK, Haraf DJ, Stenson KM, Blair EA, Witt ME, Williams R, et al. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate stage and T4N0-1 head and neck cancers. Ann Oncol. 2011;22:2304–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Hainsworth JD, Spigel DR, Greco FA, Shipley DL, Peyton J, Mark R, et al. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium. Cancer J. 2011;17:267–72.CrossRefPubMedGoogle Scholar
  52. 52.
    Yoo DS, Kirkpatrick JP, Craciunescu O, Broadwater G, Peterson BL, Carroll MD, et al. Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. Clin Cancer Res. 2012;18:1404–14.CrossRefPubMedGoogle Scholar
  53. 53.
    Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009;10:247–57.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Fury MG, Lee NY, Sherman E, Lisa D, Kelly K, Lipson B, et al. A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Cancer. 2012;118:5008–14.CrossRefPubMedGoogle Scholar
  55. 55.
    Fury MG, Xiao H, Sherman EJ, Baxi S, Smith-Marrone S, Schupak K, Gewanter R, Gelblum D, Haque S, Schoder H, Shah JP, Katabi N, Kurtzman R, Lipson B, Cox L, Lee NY, Pfister DG. Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma. Head Neck. 2015.Google Scholar
  56. 56.
    Argiris A, Kotsaki AP, Hoang T, Worden FP, Savvides P, Gibson MK, et al. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2013;24:220–5.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Chung TK, Warram J, Day KE, Hartman Y, Rosenthal EL. Time-dependent pretreatment with bevacizumab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies. Cancer Biol Ther. 2015;16:790–8.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Yao M, Galanopoulous N, Lavertu P, Fu P, Gibson M, Argiris A, et al. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced carcinoma of the head and neck. Head Neck. 2015;37:1665–71.CrossRefPubMedGoogle Scholar
  59. 59.
    Swiecicki PL, Zhao L, Belile E, Sacco AG, Chepeha DB, Dobrosotskaya I, Spector M, Shuman A, Malloy K, Moyer J, McKean E, McLean S, Wolf GT, Eisbruch A, Prince M, Bradford C, Carey T, Worden FP. A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer. Investig New Drugs. 2015.Google Scholar
  60. 60.
    Li Q, Prince ME, Moyer JS. Immunotherapy for head and neck squamous cell carcinoma. Oral Oncol. 2015;51(4):299–304.CrossRefPubMedGoogle Scholar
  61. 61.
    Jiang P, Zhang Y, Archibald SJ, Wang H. Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC. Int Immunopharmacol. 2015;28:208–14.CrossRefPubMedGoogle Scholar
  62. 62.
    Bloy N, Buque A, Aranda F, Castoldi F, Eggermont A, Cremer I, et al. Trial watch: naked and vectored DNA-based anticancer vaccines. OncoImmunology. 2015;4:e1026531.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, et al. Therapeutic cancer vaccines. Adv Cancer Res. 2014;121:67–124.CrossRefPubMedGoogle Scholar
  64. 64.
    Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer. 2008;8:108–20.CrossRefPubMedGoogle Scholar
  65. 65.
    Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst. 2012;8:599–613.CrossRefGoogle Scholar
  66. 66.
    Schuler PJ, Harasymczuk M, Visus C, DeLeo A, Trivedi S, Lei Y, et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res. 2014;20:2433–44.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Lu L, Tao H, Chang AE, Hu Y, Shu G, Chen Q, et al. Cancer stem cell vaccine inhibits metastases of primary tumors and induces humoral immune responses against cancer stem cells. OncoImmunology. 2015;9:e990767.CrossRefGoogle Scholar
  68. 68.
    Siveen KS, Kuttan G. Role of macrophages in tumor progression. Immunol Lett. 2009;123:97–102.CrossRefPubMedGoogle Scholar
  69. 69.
    Wang T, Niu G, Kottylewski M, Burdelya L, Shain K, Zhang S, et al. Regulation of the innate and adaptive immune responses by stat-3 signaling in tumor cells. Nat Med. 2004;1:48–54.CrossRefGoogle Scholar
  70. 70.
    Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting STAT3 signalling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;12:1314–21.CrossRefGoogle Scholar
  71. 71.
    Chi KH, Myers JN, Chow KC, Chan WK, Tsang YW, Chao Y, et al. Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma. Oncology. 2001;2:110–5.CrossRefGoogle Scholar
  72. 72.
    DeStefani A, Forni G, Ragona R, Cavallo G, Bussi M, Usai A, et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer. 2002;95:90–7.CrossRefGoogle Scholar
  73. 73.
    Whiteside TL, Letessier E, Hirabayashi H, Vitolo D, Bryant J, Barnes L, et al. Evidence for local and systemic activation of immune cells by peritumoral injectios of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res. 1993;53:5654–62.PubMedGoogle Scholar
  74. 74.
    Wolf GT, Fee WE, Dolan RW, Moyer JS, Kaplan MJ, Spring PM, et al. Novel neoadjuvant immunotherapt regimen safety and survival in head and neck squamous cell cancer. Head Neck. 2011;12:1666–74.CrossRefGoogle Scholar
  75. 75.
    Berinstein NL, Wolf GT, Naylor PH, Baltzer L, Egan JE, Brandwein HJ, et al. Increased lymphocyte infiltration in patients with head and neck cancer treated with IRX-2 immunotherapy regimen. Cancer Immunol Immunother. 2012;6:771–82.CrossRefGoogle Scholar
  76. 76.
    Schilling B, Halstead ES, Schuler P, Harasymczuk M, Egan JE, Whiteside TL. IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients. Cancer Immunol Immunother. 2012;9:1395–405.CrossRefGoogle Scholar
  77. 77.
    Schilling B, Harasymczuk M, Schuler P, Egan J, Ferrone S, Whiteside TL. IRX-2, a novel immunotherapeutic, enhances functions of human dendritic cells. PLoS One. 2013;2:e7234.Google Scholar
  78. 78.
    Richtsmeier WJ, Koch WM, McGuire WP, Poole ME, Chang EH. Phase I–II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma. Arch Otolaryngol Head Neck Surg. 1990;116:1271–7.CrossRefPubMedGoogle Scholar
  79. 79.
    Seixas-Silva JA, Richards T, Khuri FR, Wieand HS, Kim E, Murphy B, et al. Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long term follow-up. Arch Otolaryngol Head Neck Surg. 2005;131:304–7.CrossRefPubMedGoogle Scholar
  80. 80.
    Urba SG, Forastiere AA, Wolf GT, Amrein PC. Intensive recombinant interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous cell carcinoma. Cancer. 1993;71:2326–31.CrossRefPubMedGoogle Scholar
  81. 81.
    Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26:234–41.CrossRefPubMedGoogle Scholar
  82. 82.
    Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925–31.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys. 2013;85:293–5.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Chandra RA, Wilhite TJ, Balboni TA, Alexander BM, Spektor A, Ott PA, et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. OncoImmunology. 2015;4:e1046028.CrossRefPubMedGoogle Scholar
  85. 85.
    Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7:455–65.CrossRefPubMedGoogle Scholar
  86. 86.
    Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003;63:4342.PubMedGoogle Scholar
  87. 87.
    Andre N, Carre M, Pasquier E. Metronomics: towards personalized chemotherapy. Nat Rev Clin Oncol. 2014;11:413–31.CrossRefPubMedGoogle Scholar
  88. 88.
    Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol. 2008;20:504–11.CrossRefPubMedGoogle Scholar
  89. 89.
    Kaneno R, Shurin GV, Tourkova IL, Shurin MR. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J Transl Med. 2009;10:58.CrossRefGoogle Scholar
  90. 90.
    Kaneno R, Shurin GV, Kaneno FM, Naiditch H, Luo J, Shurin MR. Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell Oncol. 2011;34:97–106.CrossRefGoogle Scholar
  91. 91.
    Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4 + CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641–8.CrossRefPubMedGoogle Scholar
  92. 92.
    Kan S, Hazama S, Maeda K, Inoue Y, Homma S, Koido S, et al. Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res. 2012;32:5363–9.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2016

Authors and Affiliations

  1. 1.Department of Otolaryngology-Head and Neck SurgeryUniversity of Michigan Comprehensive Cancer CenterAnn ArborUSA

Personalised recommendations